Author: de Lemos Neto, Miguel; Alexandre, Rafael Costa Vieira; Morra, Rafaela Oliveira Gallart; da Paz, Juliana Aparecida Souza; Barroso, Shana Priscila Coutinho; Resende, Angela Castro; de Medeiros-Lima, Daniel J. M.; Alexandre, Pedro Celso Braga
Title: Use of glucocorticoids and azithromycin in the therapy of COVID-19 Cord-id: 6etri9my Document date: 2021_6_4
ID: 6etri9my
Snippet: In December 2019, a new variant coronavirus, SARS-CoV-2, emerged in China, which was initially described as a pneumonia of an unknown agent. The new coronavirus spreads mainly by person-to-person transmission through close contact. The pathophysiology of COVID-19 is related to a complex immune system response that varies between people and, in severe cases of the disease, is characterized by excessive responses called “cytokine storms,†which are associated with complications that can lead t
Document: In December 2019, a new variant coronavirus, SARS-CoV-2, emerged in China, which was initially described as a pneumonia of an unknown agent. The new coronavirus spreads mainly by person-to-person transmission through close contact. The pathophysiology of COVID-19 is related to a complex immune system response that varies between people and, in severe cases of the disease, is characterized by excessive responses called “cytokine storms,†which are associated with complications that can lead to a state of hypercoagulation and death. Glucocorticoids and azithromycin are drugs that may be effective in the treatment. This review aims to highlight the clinical findings that demonstrate the effectiveness of glucocorticoid and azithromycin therapy in the treatment of COVID-19. To date, many drugs have been studied for use in combination therapy, and the rapid expansion of knowledge about the virology of SARS-CoV-2 generates a more accurate direction in therapy.
Search related documents:
Co phrase search for related documents- abundant membrane protein and acute respiratory syndrome: 1, 2, 3, 4
- action mechanism and acute phase protein: 1, 2
- action mechanism and acute pneumonia: 1, 2, 3, 4, 5, 6
- action mechanism and acute pneumonia respiratory distress: 1, 2
- action mechanism and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- action mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- action mechanism and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- action mechanism and low dose dexamethasone: 1
- action mechanism and low respiratory: 1
- action mechanism and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- action mechanism and lung infiltration: 1, 2
- action mechanism and lung inflammation: 1, 2, 3, 4, 5, 6, 7
- action mechanism and lung inflammation suppress: 1
- action mechanism and lung target: 1
- action mechanism and macrolide antibiotic: 1, 2
- action mechanism and macrophage neutrophil: 1
- action mechanism and macrophage response: 1
- activate leukocyte and adaptive immunity: 1
Co phrase search for related documents, hyperlinks ordered by date